Purple Biotech (PPBT) Price & Analysis

Compare

1,100 Followers

PPBT Stock Chart & Stats

$0.69

-$0.22(-5.25%)

At close: Jan 08 4:00 PM EST

$0.69

-$0.22(-5.25%)

Day’s Range― - ―

52-Week Range$0.53 - $4.55

Previous CloseN/A

Volume16.93K

Average Volume (3M)415.61K

Market Cap

$6.48M

Enterprise Value-$9.32M

Total Cash (Recent Filing)$10.45M

Total Debt (Recent Filing)$256.00K

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Feb 11, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding9,292,398

10 Day Avg. Volume296,099

30 Day Avg. Volume415,608

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.37

Price to Sales (P/S)0.00

P/FCF Ratio-0.84

Enterprise Value/Market Cap-1.44

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit63.75

Enterprise Value/Ebitda2.62

Forecast

1Y Price Target

$34.00

Price Target Upside4827.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker AnalysisVarious biomarker analysis on the Phase 2 CM24 trial demonstrates improved overall survival.

Efficacy Of CM24The CM24 experimental arm had consistently greater efficacy for every evaluated endpoint.

Bears Say

Imbalance In Clinical TrialThe CM24 + nivolumab + gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms.

Purple Biotech News

Purple Biotech’s antibody platform shows anti-tumor activity

Purple Biotech (PPBT) reported positive new preclinical data from its CAPTN-3 tri-specific antibody platform presented at the ESMO...

27d ago

PPBT

Purple Biotech Shareholders Approve Key Proposals at December Meeting

Purple Biotech ( ($PPBT) ) has shared an update. On December 15, 2025, Purple Biotech Ltd. held an...

21d ago

PPBT

Purple Biotech Announces Positive Preclinical Data at ESMO IO Congress 2025

Purple Biotech ( ($PPBT) ) has provided an update. On December 11, 2025, Purple Biotech reported positive preclinical...

27d ago

PPBT

Purple Biotech Unveils November 2025 Corporate Presentation Highlighting Oncology Advances

The latest update is out from Purple Biotech ( ($PPBT) ). On November 19, 2025, Purple Biotech Ltd....

2M ago

PPBT

Promising Advancements and Strategic Developments Drive Buy Rating for Purple Biotech

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Purple Biotech, with...

2M ago

PPBT

Purple Biotech Announces Q3 2025 Financial Results and Advances CAPTN-3 Platform

Purple Biotech ( ($PPBT) ) just unveiled an update. On November 14, 2025, Purple Biotech announced its third-quarter...

2M ago

PPBT

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

“During the quarter, we secured the necessary funds to support the development of our CAPTN-3 technology platform through...

2M ago

PPBT

Purple Biotech sees cash runway into 1H27

As of September 30, 2025, Purple Biotech (PPBT) had cash and cash equivalents and short-term deposits of $10.5...

2M ago

PPBT

PPBT Earnings this Week: How Will it Perform?

Purple Biotech Ltd. (PPBT) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

2M ago

PPBT

3 Penny Stocks to Watch Now, 10/30/25

Cambium Networks, Purple Biotech, and Ernexa Therapeutics are the 3 Penny Stocks to watch on October 30, 2025, based on TipRanks’...

2M ago

CMBM

ERNA

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Traders have loads of stock market news to read on Wednesday as earnings and other topics dominate today’s headlines. ...

2M ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

Purple Biotech stock gained on Wednesday after the company reached a production milestone. ...

2M ago

PPBT

Purple Biotech Reaches Manufacturing Milestone for IM1240 Antibody

Purple Biotech ( ($PPBT) ) has shared an announcement. On October 29, 2025, Purple Biotech announced a significant...

2M ago

PPBT

Purple Biotech achieves manufacturing milestone for IM1240

Purple Biotech (PPBT) announced the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3...

2M ago

PPBT

PPBT FAQ

What was Purple Biotech’s price range in the past 12 months?

Purple Biotech lowest stock price was $0.53 and its highest was $4.55 in the past 12 months.

What is Purple Biotech’s market cap?

Purple Biotech’s market cap is $6.48M.

When is Purple Biotech’s upcoming earnings report date?

Purple Biotech’s upcoming earnings report date is Feb 11, 2026 which is in 35 days.

How were Purple Biotech’s earnings last quarter?

Purple Biotech released its earnings results on Nov 14, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.03.

Is Purple Biotech overvalued?

According to Wall Street analysts Purple Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Purple Biotech pay dividends?

Purple Biotech does not currently pay dividends.

What is Purple Biotech’s EPS estimate?

Purple Biotech’s EPS estimate is -0.34.

How many shares outstanding does Purple Biotech have?

Purple Biotech has 9,292,398 shares outstanding.

What happened to Purple Biotech’s price movement after its last earnings report?

Purple Biotech reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -2.703%.

Which hedge fund is a major shareholder of Purple Biotech?

Currently, no hedge funds are holding shares in PPBT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech (PPBT) Earnings & Revenues

Historic Earnings Reports

PPBT Stock 12 Month Forecast

Average Price Target

$34.00

▲(4827.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","26":"$26","35":"$35","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,8,17,26,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,3.4184615384615387,5.966923076923077,8.515384615384615,11.063846153846153,13.612307692307692,16.160769230769233,18.70923076923077,21.25769230769231,23.806153846153848,26.354615384615386,28.903076923076924,31.451538461538465,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,3.4184615384615387,5.966923076923077,8.515384615384615,11.063846153846153,13.612307692307692,16.160769230769233,18.70923076923077,21.25769230769231,23.806153846153848,26.354615384615386,28.903076923076924,31.451538461538465,{"y":34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,3.4184615384615387,5.966923076923077,8.515384615384615,11.063846153846153,13.612307692307692,16.160769230769233,18.70923076923077,21.25769230769231,23.806153846153848,26.354615384615386,28.903076923076924,31.451538461538465,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.52,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.49,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >